title: Is Europe ready to embrace a policy of universal varicella vaccination?
abstract: For the first time, a live attenuated varicella vaccine with an indication for universal vaccination is licensed in all EU countries. It is now time to consider whether in Europe there should be widespread vaccination against varicella to prevent this common and highly infectious disease. Increasing numbers of countries are adopting vaccination programmes against the disease. In those countries where a routine vaccination policy has been adopted, the success of the vaccine has been significant. The USA, which prior to the launch of a universal vaccination programme in 1995 had 4 million cases of varicella per year, has seen a dramatic reduction in varicella morbidity and mortality rates. A universal varicella vaccination policy is an option that needs to be considered for Europe not only in medical terms but also because it would be socially and economically appropriate.
authors.affiliation: Universiteit Antwerpen, UZA and Paola Kinderziekenhuis ZNA, Antwerp, Belgium. jose.ramet@zna.be
authors.forename: J
authors.initials: J
authors.lastname: Ramet
authors.forename: C
authors.initials: C
authors.lastname: Weil-Olivier
authors.forename: W
authors.initials: W
authors.lastname: Sedlak
mesh_terms: D000293:Adolescent; D000328:Adult; D002644:Chickenpox / Q000453:epidemiology / Q000517:prevention & control*; D019433:Chickenpox Vaccine / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D005060:Europe / Q000453:epidemiology; D006562:Herpes Zoster / Q000517:prevention & control; D006801:Humans; D017589:Immunization Programs; D007115:Immunization Schedule; D007223:Infant
chemical_list: D019433:Chickenpox Vaccine